Document is current
Any future updates will be listed below
-
Authors
Yan, Wenjing
Wang, Shizhi https://orcid.org/0000-0002-6083-6753
Hao, Haibin
Lin, Hong
Wang, Chen https://orcid.org/0000-0001-6461-1271
Xie, Shuqian
Zhang, Xing
Lu, Yiran
Ding, Xin
Chen, Xue
Liu, Haohan
Zhang, Guiyuan
Wei, Dong
Ma, ChangYan
Tang, Cheng
Li, Xiuting
Yu, Bingjia
Hu, Jing
Gu, Zhongze https://orcid.org/0000-0001-8926-7710
Yu, Evan Yi-Wen https://orcid.org/0000-0001-7825-5087
Li, Weiqin
Xia, Jiang https://orcid.org/0000-0001-8112-7625
Zhang, Hao https://orcid.org/0000-0001-9744-1707
-
Funding
Funding for this research was provided by:
ITF TCFS grant GHP/074/20SZ; CUHK internal grants
- License Information
-
More Information
Article History
Received: 5 December 2024
Accepted: 24 February 2026
First Online: 10 March 2026
Competing interests
: This research has been filed for a patent under application number CN116769718A with W.Y. and H.Z. named as inventors. J.X. and H.Z. co-founded EVLiXiR Biotech Inc., where H.Z. serves as CEO and J.X. as chief scientist. All other authors declare no conflicts of interest.
